Amedisys, Inc. (NASDAQ:AMED) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
On October5, 2017, Gary Willis resigned as the Chief Financial Officer of Amedisys, Inc. (the “Company”) and accepted an Executive Vice President and Chief Financial Officer position with another healthcare company.
On October5, 2017, the Board of Directors of the Company appointed Scott G. Ginn, currently the Company’s Chief Accounting Officer, as the Company’s Chief Financial Officer, effective immediately. Mr.Ginn, age 48, has served as the Company’s Chief Accounting Officer since February 2017. He previously served as the Company’s Senior Vice President of Finance and Accounting from October 2015 to February 2017 and Senior Vice President of Accounting and Controller from April 2007 to October 2015. Prior to joining the Company, he was a Director at Postlethwaite& Netterville, a professional accounting corporation. Mr.Ginn is a Certified Public Accountant.
Mr.Ginn will participate in the Amedisys Holding, L.L.C. Severance Plan for Key Executives dated April30, 2015, as amended. Mr.Ginn does not have a family relationship with any of the current officers or directors of the Company. There is no currently proposed transaction, and since the beginning of fiscal year 2016 there has not been any transaction, involving the Company and Mr.Ginn which was a related person transaction within the meaning of Item 404(a) of Regulation S-K.
| Item 5.02. | Regulation FD Disclosure. |
On October6, 2017, the Company issued a press release announcing the resignation of Mr.Willis and the appointment of Mr.Ginn as the Company’s Chief Financial Officer, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.
The information included in this Current Report on Form 8-K under this Item 5.02 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 5.02 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
| Item 5.02. | Financial Statements and Exhibits. |
(d) Exhibits.
|
Exhibit Number |
Description |
| 99.1 | Press Release dated October6, 2017 |
AMEDISYS INC ExhibitEX-99.1 2 d461611dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Contact: Kendra Kimmons Vice President of Marketing & Communications 225-299-3708 [email protected] Scott Ginn Promoted to Chief Financial Officer at Amedisys BATON ROUGE,…To view the full exhibit click here
About Amedisys, Inc. (NASDAQ:AMED)
Amedisys, Inc. (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks. The Company’s hospice segment provides palliative care and comfort to terminally ill patients and their families. The Company’s personal care segment provides patients with assistance with the essential activities of daily living. The Company owns and operates approximately 330 Medicare-certified home healthcare centers, over 80 Medicare-certified hospice care centers and approximately nine personal-care care centers in over 30 states within the United States, the District of Columbia and Puerto Rico.
